Arizona Economic Burden of Valley Fever Totals $736 Million

Feb 9, 2021

TUCSON, Ariz. — A University of Arizona Health Sciences study has estimated total lifetime costs at $736 million for the 10,359 valley fever patients diagnosed in Arizona in 2019, underscoring the economic burden the disease places on the state and its residents.

Amy Grizzle, PharmD (Photo: University of Arizona College of Pharmacy)The prevalence of valley fever, formally known as coccidioidomycosis or cocci, has increased in recent years, from 5,624 cases diagnosed in Arizona in 2014 to 10,359 cases in 2019. There currently are no certain means of prevention or vaccination for the fungal disease, which is caused by spores of Coccidioides, a family of fungi found in soils of the Southwest.

The findings highlight the need for a vaccine, better therapeutic options and more consistent use of rapid diagnostic testing – all areas of focus at the UArizona College of Medicine – Tucson’s Valley Fever Center for Excellence. The study, “Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis,” was recently published in the journal Open Forum Infectious Diseases.

“I was overwhelmed by how important this disease is in Arizona and how preventable some of the costs may be,” said lead author Amy Grizzle, PharmD, associate director of the Center for Health Outcomes & PharmacoEconomic Research (or HOPE Center) in the UArizona College of Pharmacy. “Because it’s kind of an isolated disease, I didn’t necessarily think it was that expensive. I’m gratified that this study was able to shed some light on how many people this disease affects and how costly it is, especially taking into consideration some of the long-term complications.”

Dr. Grizzle said she was surprised by the $736 million total, which can be broken down into direct and indirect costs of $671 million and $65 million, respectively. Among direct costs, she said, are health expenses expected over a person’s lifetime, including hospitalization, diagnosis and treatment (chest X-rays, rapid diagnostic tests, medications, surgery, etc.), and follow-up care including skilled nursing facilities for rehabilitation. Indirect costs include short-term work loss and lost earnings due to premature mortality.

The study examined the cost-of-illness for valley fever’s five primary manifestations:

  • Primary uncomplicated pneumonia, which comprises 85% of diagnosed valley fever cases;
  • Chronic pneumonia, which often requires treatment for two to three years;
  • Disseminated infection, which requires lifelong medication, periodic testing, and recurring hospitalization, and is the leading cause of death among valley fever patients;
  • Other pulmonary changes – pulmonary nodules, which account for about 7% of all valley fever cases; and,
  • Other pulmonary changes – pulmonary cavities, which affect about 3% of all valley fever patients. Patients with pulmonary changes, whether nodules or cavities, often require expensive diagnostics to rule out lung cancer, and about 40% of such cases require hospitalization.

Researchers found that severe cases of valley fever where the disease spreads to other parts of the body, known as disseminated valley fever, resulted in the highest economic burden at nearly $1.4 million per person.

John N. Galgiani, MD (Photo: University of Arizona Health Sciences)

The study’s estimated lifetime costs are comparable to a 2019 California study that put total lifetime costs for the 7,466 people diagnosed with Valley fever in the Golden State in 2017 at just under $700 million, according to co-author John Galgiani, MD, an infectious diseases specialist with the College of Medicine – Tucson who also is director of the UArizona Valley Fever Center for Excellence and a member of the BIO5 Institute.

Leslie Wilson, PhD, of the University of California San Francisco, led the California study and is a co-author on the Arizona study along with Drs. Grizzle and Galgiani, and David Nix, PharmD, of the UArizona College of Pharmacy.

Dr. Galgiani, who founded the Valley Fever Center in 1996, said two-thirds of all valley fever cases reported in the U.S. occur in Arizona, with half in Maricopa County. Only about 5% of U.S. valley fever cases are reported outside of Arizona and California.

The primary symptoms of valley fever are respiratory problems similar to bacterial pneumonia, though more serious complications can arise when the infection spreads beyond the lungs to other areas including bones, joints, and the brain and central nervous system.

David Nix, PharmD (University of Arizona College of Pharmacy)

Delays in diagnosis are common because valley fever symptoms can mimic those of the flu or bacterial pneumonia. Such confusion often means ineffective treatment with antibiotics, instead of antifungals like fluconazole, for days or weeks, during which time a patient’s condition might deteriorate. The situation has worsened with the emergence of COVID-19, Dr. Galgiani said.

“Basically, doctors were under-diagnosing valley fever in the springtime, because of several reasons. One, people were being tested for COVID and, when they were negative, they didn’t do any more testing,” Dr. Galgiani said. “And two, people weren’t seeking hospital care for anything if they didn’t think it was COVID.”

Drs. Galgiani and Grizzle say the economic impacts highlighted in the study underscore the value of supporting research into developing more rapid diagnostic tests, better therapies and ultimately a preventative vaccine to address this important public health problem in Arizona.

“Hopefully, after more treatments and/or a vaccine are available, we can do another cost of illness analysis 10 years from now and see that these medications have greatly reduced the economic burden to Arizona,” Dr. Grizzle said.

# # #

Photos available: https://arizona.box.com/s/m9cswnlh2f767lpoefi68ivz7rgrhje4

RELATED LINKS:

UA Expertise on Valley Fever (Coccidioidomycosis)

Is It Valley Fever or Is It COVID-19?

About the University of Arizona College of Medicine – Tucson
The University of Arizona College of Medicine – Tucson is shaping the future of medicine through state-of-the-art medical education programs, groundbreaking research and advancements in patient care in Arizona and beyond. Founded in 1967, the college boasts more than 50 years of innovation, ranking among the top medical schools in the nation for research and primary care. Through the university's partnership with Banner Health, one of the largest nonprofit health care systems in the country, the college is leading the way in academic medicine. For more information, stvisit medicine.arizona.edu (Follow us: Facebook | Twitter | Instagram | LinkedIn).

About the University of Arizona College of Pharmacy
The University of Arizona College of Pharmacy is the premier pharmacy college in the Southwest, and one of the top in the nation, focused on drug discovery, toxicology, pharmaceutics, health outcomes and sciences, pharmaceutical education and research through interprofessional training and collaborative public/private partnerships. Preparing pharmacists and pharmaceutical scientists in undergraduate, professional, graduate and post-doctoral programs, the college embraces an entrepreneurial spirit, providing tailored educational opportunities to broaden students' experiences. Established 72 years ago as the first health sciences college at UArizona, the college has a long history of improving science and health, both in Arizona and around the world. It is currently ranked No. 8 among the nation’s 143 colleges of pharmacy by the American Association of Colleges of Pharmacy. For more information: pharmacy.arizona.edu (Follow us: Facebook | Twitter | Instagram | YouTube).

About the University of Arizona Health Sciences
The University of Arizona Health Sciences is the statewide leader in biomedical research and health professions training. UArizona Health Sciences includes the Colleges of Medicine (Tucson and Phoenix), Nursing, Pharmacy, and the Mel and Enid Zuckerman College of Public Health, with main campus locations in Tucson and the Phoenix Biomedical Campus in downtown Phoenix. From these vantage points, Health Sciences reaches across the state of Arizona, the greater Southwest and around the world to provide next-generation education, research and outreach. A major economic engine, Health Sciences employs nearly 5,000 people, has approximately 4,000 students and 900 faculty members, and garners $200 million in research grants and contracts annually. For more information: uahs.arizona.edu (Follow us: Facebook | Twitter | YouTube | LinkedIn | Instagram).

Original Story Link: